Core Viewpoint - Aalberts has initiated a share buyback program, repurchasing a total of 214,849 shares for EUR 6,446,494.52 at an average price of EUR 30.00 per share during the specified period [1][2]. Group 1: Share Buyback Program Details - The share buyback program was announced on 26 February 2026, with a total budget of EUR 75 million [2]. - The repurchase of shares began on 27 February 2026 and is scheduled to be completed by 9 October 2026 [2]. - As of 27 March 2026, a cumulative total of 883,622 shares has been repurchased under the program, amounting to EUR 27,976,238 [2]. Group 2: Execution and Compliance - Aalberts has engaged an intermediary to conduct the share repurchases in the open market, independent of the company [3]. - The buyback will be executed within the authority granted by the Annual General Meeting (AGM) on April 10, 2025 [3]. - The program will adhere to the Market Abuse Regulation 596/2014 and the safe harbour parameters set by the Commission Delegated Regulation 2016/1052 for share buybacks [3].

Core Insights - Super Hi International Holding Ltd. reported its unaudited financial results for Q4 and the full year of 2025, highlighting growth in revenue and operational metrics despite challenges in operating margins [1][4][6]. Fourth Quarter 2025 Highlights - Revenue for Q4 2025 was US$230.0 million, a 10.2% increase from US$208.8 million in Q4 2024 [6][7]. - Haidilao restaurant's revenue grew by 6.0% year-over-year, with same-store sales rising by 2.3% [4][14]. - The overall average table turnover rate improved to 4.0 times per day, up from 3.9 times per day in Q4 2024 [6][10]. - The company opened 3 new Haidilao restaurants and closed 3, resulting in a net increase of 4 restaurants, totaling 126 as of December 31, 2025 [6][10]. Full Year 2025 Highlights - Total revenue for 2025 reached US$840.8 million, an 8.0% increase from US$778.3 million in 2024 [13][19]. - Revenue from Haidilao restaurant operations was US$790.0 million, reflecting a 5.7% increase from US$747.3 million in 2024 [13][19]. - The overall average table turnover rate for the year was 3.9 times per day, compared to 3.8 times per day in 2024 [13][18]. - The company reported a profit of US$36.3 million for the year, a significant increase of 69.6% from US$21.4 million in 2024, primarily due to a net foreign exchange gain [19][20]. Operational Performance - The total number of guest visits in 2025 exceeded 32.0 million, a 7.0% increase from 29.9 million in 2024 [6][19]. - The restaurant level operating margin for 2025 was 8.7%, down from 10.1% in 2024, attributed to strategic investments in employee incentives and enhanced customer experiences [5][18]. - Staff costs for the year were US$285.4 million, a 10.1% increase from US$259.3 million in 2024, reflecting the expansion of the restaurant network and increased guest visits [17][18]. Revenue Breakdown - Revenue from the delivery business in 2025 was US$19.0 million, a 68.1% increase from US$11.3 million in 2024, driven by optimization of delivery services [24]. - Revenue from other business segments reached US$31.8 million, a 61.4% increase from US$19.7 million in 2024, largely due to the popularity of Haidilao-branded products [24]. Restaurant Network Expansion - As of December 31, 2025, the company operated 126 Haidilao restaurants across 14 countries, marking a strategic expansion in its international footprint [44]. - The company continues to focus on enhancing its brand influence and diversifying its revenue streams through initiatives like the "Pomegranate Plan" [5][24].

Core Insights - Beta Bionics has launched Bionic Insights™, a feature within its Bionic Reports aimed at enhancing treatment recommendations for diabetes patients [1][2] - This innovation positions Beta Bionics as the first insulin pump company to provide advanced intelligent reporting, allowing clinicians to interpret patient data more effectively [2][3] Group 1: Product Features - Bionic Insights offers a structured approach to data by categorizing information into Areas of Success and Areas of Opportunity, enabling clinicians to quickly identify factors influencing glucose outcomes [4][7] - The feature transforms complex data into clear, actionable guidance, facilitating more productive conversations between clinicians and patients [3][5] Group 2: Clinical Impact - The introduction of Bionic Insights is expected to improve glucose control for patients by providing healthcare providers with unprecedented clarity on treatment effectiveness and areas needing support [2][3] - By enhancing the understanding of patient data, Bionic Insights aims to foster better communication and targeted recommendations, ultimately improving patient outcomes [5][6] Group 3: Company Overview - Beta Bionics, headquartered in Irvine, California, is focused on revolutionizing diabetes care through innovative solutions like the iLet Bionic Pancreas, which features a closed-loop algorithm for insulin delivery [6] - The company's mission is to simplify diabetes management and improve the quality of life for individuals living with diabetes [6]

Core Insights - LENSAR, Inc. reported a 48% increase in the installed base of its ALLY Robotic Cataract Laser Systems, reaching approximately 200 systems by the end of 2025, with a backlog of 13 systems pending installation [1][4] - The company achieved recurring revenue of over $46.3 million for the full year, reflecting a 15% increase compared to 2024, with 79% of total revenue derived from recurring sources [1][3][5] - Total revenue for Q4 2025 decreased by approximately $0.7 million, or 4%, compared to Q4 2024, primarily due to a $2.6 million decline in system revenue, although worldwide procedure volume increased by approximately 20% [3][5] Financial Performance - For Q4 2025, total revenue was $16.025 million, down from $16.731 million in Q4 2024, while total revenue for the full year was $58.435 million, up from $53.494 million in 2024 [5][24] - Recurring revenue for Q4 2025 increased by $1.9 million, or 17%, compared to Q4 2024, contributing to a total recurring revenue of $46.306 million for the year [3][5] - The net loss for Q4 2025 was $1.5 million, or ($0.12) per share, significantly reduced from a net loss of $18.7 million, or ($1.61) per share, in Q4 2024 [9][24] Operational Highlights - The company placed 15 ALLY Systems in Q4 2025, contributing to a total installed base of approximately 200 systems, which is a 48% increase from the end of 2024 [4][5] - Worldwide procedure volume for 2025 increased by 22% compared to 2024, indicating robust growth in both U.S. and international markets [2][3] - Selling, general, and administrative expenses rose to $10.3 million in Q4 2025, an increase of 51% from $6.8 million in Q4 2024, primarily due to acquisition-related costs [6][8] Cash and Liabilities - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $18.0 million, down from $22.5 million at the end of 2024 [11] - Current liabilities increased significantly to $40.574 million as of December 31, 2025, compared to $15.003 million at the end of 2024, largely due to acquisition-related costs [26] Strategic Direction - The company aims to expand its share in the laser-assisted cataract surgery market and enhance the overall robotic laser cataract market, demonstrating confidence in its ALLY System's value [2] - Following the termination of the merger agreement with Alcon, the company retains a merger deposit of $10 million, which will be recorded as other income [12]

Core Insights - T1 Energy Inc. reported significant advancements in 2025, including the establishment of a vertically integrated solar platform and securing over $440 million in strategic capital to enhance its competitive position [3][6] - The company achieved record production and sales at its G1_Dallas facility, producing 1.13 GW and generating net sales of $358.5 million in Q4 2025 [6][11] - T1 Energy is on track to start production at its G2_Austin facility in Q4 2026, with an estimated capital spending requirement of approximately $350 million for Phase 1 [6][10] Financial Performance - T1 Energy reported a net loss attributable to common stockholders of $190.0 million, or $(0.87) per share, for Q4 2025, a decrease from a net loss of $367.2 million, or $(2.59) per share, in Q4 2024 [16][27] - For the full year 2025, the net loss attributable to stockholders was $380.8 million, or $2.19 per diluted share, compared to a net loss of $450.2 million, or $3.20 per diluted share, in 2024 [16][27] - The company had cash, cash equivalents, and restricted cash of $270.8 million as of December 31, 2025, with $182.5 million being unrestricted cash [16][27] Operational Highlights - T1 Energy's G1_Dallas facility produced a total of 2.79 GW in 2025, aligning with previous guidance of 2.6 – 3.0 GW [6][11] - The company has contracted 3 GW of production for 2026, with a production and sales guidance of 3.1 – 4.2 GW [9][10] - T1 Energy commenced construction on the 2.1 GW Phase 1 of the G2_Austin facility, with steel erection planned to start in April 2026 [6][10] Strategic Developments - T1 Energy executed a long-term offtake agreement with Treaty Oak Clean Energy for a minimum of 900 MW of solar modules [9][10] - The company successfully sold $160 million in Section 45X production tax credits at a price of $0.91 per dollar generated [9][10] - T1 Energy's board appointed Robert Hammond as an independent director, bringing over 40 years of energy industry experience [4][5]

Core Insights - Fennec Pharmaceuticals announced the grant of incentive stock options to 24 new non-executive employees as part of its 2026 Equity Inducement Plan, totaling 377,500 shares [1][2] Group 1: Stock Options and Inducement Plan - The incentive stock options (ISOs) have an exercise price of $5.77 per share, equal to the closing price on March 30, 2026, and a term of ten years from the grant date [3] - One-third of the shares underlying each ISO will vest on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the following 24 months, contingent on continued employment [3] Group 2: Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, with its primary product being PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity [4] - PEDMARK received FDA approval in September 2022, followed by European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI [4] - In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand, with the product already available in the U.K. and Germany [5]

Core Insights - Sound Group Inc. reported a remarkable 53% year-over-year increase in net revenues for fiscal year 2025, returning to profitability, driven by growth in its audio-centric ecosystem and AI initiatives [2][7][20]. Financial Highlights - **Second Half 2025 Financial Results**: - Net revenues reached RMB 1,745.1 million (US$ 249.5 million), a 58% increase from RMB 1,107.8 million in the same period of 2024 [3][7]. - Gross profit was RMB 513.1 million (US$ 73.4 million), reflecting a 65% increase from RMB 310.5 million in the same period of 2024 [5][7]. - Operating income was RMB 153.8 million (US$ 22.0 million), compared to an operating loss of RMB 45.4 million in the same period of 2024 [12][7]. - **Fiscal Year 2025 Financial Results**: - Total net revenues were RMB 3,102.8 million (US$ 443.7 million), a 53% increase from RMB 2,031.8 million in 2024 [20][32]. - Gross profit for the year was RMB 905.2 million (US$ 129.4 million), a 63% increase from RMB 556.9 million in the prior year [23][32]. - Net income was RMB 220.6 million (US$ 31.6 million), compared to a net loss of RMB 81.0 million in 2024 [32][34]. Operational Highlights - The company enhanced user engagement by expanding audio content offerings and deploying AI technologies to optimize operational efficiency [2]. - Significant investments were made in voice AI technologies, including automatic speech recognition and real-time audio intelligence [2]. - The launch of SoundSphereAI in January 2026 showcased the company's technological capabilities within the SoundSphere ecosystem [2]. Dividend Announcement - The Board of Directors declared a special cash dividend of approximately US$ 5 million, reaffirming the company's commitment to returning value to shareholders [2][36].

Core Insights - Neinor Homes has entered a joint venture with Stoneshield Capital to develop a premium residential project in Marbella, marking its entry into the high-end residential segment and expanding its Asset Management platform [1][3] Group 1: Project Details - The development will consist of 262 homes across more than 60,000 sqm, located near Río Real Golf Course and close to Marbella city center, Puerto Banús, and the beach [2] - The project will include a 1,200 sqm Private Members Club featuring wellness areas, pools, sports facilities, and landscaped spaces [2] - Expected revenues from the project are projected to exceed €600 million over the next five years, making it one of the largest residential developments in Marbella in recent years [2] Group 2: Joint Venture Structure - Under the joint venture, Stoneshield will hold a 70% stake while Neinor will hold 30%, with Neinor acting as the delegated developer throughout the development lifecycle [3] - The investment reflects strong fundamentals in Marbella, driven by robust international demand and limited land supply [3] Group 3: Strategic Commentary - Borja García-Egotxeaga, CEO of Neinor Homes, emphasized the strength of the partnership, combining development expertise with institutional capital to deliver high-quality projects [4] - Juan Pepa, Founding Partner of Stoneshield Capital, highlighted Spain's attractiveness as a residential investment market, with Marbella being a standout location [4]

Core Viewpoint - CSG is acquiring a 49% stake in Hirtenberger Defence Systems (HDS) from 4iG, enhancing its product portfolio in mortar ammunition and systems, and marking its first acquisition in Austria [1][3]. Group 1: Acquisition Details - The acquisition significantly expands CSG's product offerings in mortar ammunition and systems, strengthening its production capabilities in Europe [1][3]. - The agreement is part of a broader strategic partnership between CSG and 4iG, which may include a joint venture in Slovakia for assembly and international business activities [1][6]. Group 2: HDS Overview - HDS is a traditional European manufacturer specializing in mortar systems and ammunition in 60, 81, and 120 mm calibers, with a diverse portfolio including high-explosive fragmentation and training rounds [2][14]. - The company has over 160 years of heritage and is recognized for its advanced technological capabilities in mortar systems and ammunition [5][8]. Group 3: Strategic Implications - The transaction aligns with CSG's long-term strategy to enhance production capacities, technological expertise, and vertical integration in ammunition and land systems manufacturing [3][11]. - The acquisition will enable CSG to better control its supply chain and optimize production across its group, enhancing efficiency in both component and final product manufacturing [11][12]. Group 4: Technological Advancements - HDS contributes advanced digital fire control systems that allow precise targeting and integration into modern Battle Management Systems, enhancing CSG's overall technological portfolio [10][12]. - The combination of HDS's technological know-how and CSG's production capabilities will strengthen their position as a major player in the European land systems and ammunition market [12].

Core Insights - West Red Lake Gold Mines Ltd. announced positive drill results from its infill and conversion drilling program at the Rowan Project, which is fully funded and 100% owned by the company [1][2][26] - The results indicate potential for increased daily mined tonnage and improved project economics by incorporating additional veins into the production profile [2][30] Drilling Program Overview - A total of 37 holes were drilled, covering approximately 6,300 meters, with fire assay results reported for 26 holes and results pending for 11 holes [3][27] - The drilling program aims to upgrade Inferred resources to Indicated and provide data for a combined Pre-Feasibility Study (PFS) for the Madsen Mine and Rowan Project [27][30] Significant Drill Results - Notable intercepts include: - Hole RLG-26-212: 1.62m at 19.83 g/t Au, including 0.62m at 51.50 g/t Au [7][10] - Hole RLG-26-210: 1m at 30.59 g/t Au, including 0.5m at 61.10 g/t Au [7][10] - Hole RLG-25-206: 0.5m at 41.50 g/t Au [10] - The results highlight the high-grade potential of the Rowan vein system, with visible gold associated with quartz veining in several holes [7][10] Economic Potential - The 2025 Preliminary Economic Assessment (PEA) projected an underground mine at Rowan producing an average of 35,230 ounces of gold per year at an average grade of 8.0 g/t Au [26] - Incorporating additional veins could extend the mine life and allow for earlier ore extraction, positively impacting the net present value (NPV) of the project [30][31] Resource Estimates - The current mineral resource estimate includes an Indicated resource of 478,707 tonnes containing 196,747 ounces of gold at a grade of 12.78 g/t Au, and an Inferred resource of 421,181 tonnes containing 118,155 ounces at 8.73 g/t Au [40][41] - The estimates are based on a cut-off grade of 3.80 g/t Au and a gold price of US$1,800/oz [40][41] Future Plans - The company plans to conduct further geotechnical, metallurgical, and engineering studies to support the PFS, with permitting efforts aimed at advancing Rowan towards Advanced Exploration status by 2027 [31][32] - The Advanced Exploration permit is expected to facilitate bulk sample extraction and underground mine development [32][31]